Patents Issued in June 1, 2010
-
Patent number: 7727522Abstract: The invention relates to retroviral vectors (known as lentiviral vectors), which are used to transfer genes into cells that are at cell cycle stage G0, to methods for their production and to the use thereof for transferring genes into mammalian cells. Said vectors are derived from SIVsmmPBj14 (simian immunodeficiency virus) of the sooty mangabey monkey, strain PBj 14.Type: GrantFiled: April 3, 2003Date of Patent: June 1, 2010Inventors: Klaus Cichutek, Michael Muehlebach, Matthias Schweizer
-
Patent number: 7727523Abstract: Methods are provided for suppressing the immune system response in recipients of transplanted organs, tissues or cells. An extracorporeal quantity of blood from the intended transplant recipient is treated to induce monocytes contained in the blood to differentiate and form dendritic cells. The maturation of the dendritic cells is truncated at a stage where the dendritic cells can inactivate T cell clones which would otherwise generate an undesired immune system response. The immature dendritic cells can be directly administered to the transplant recipient, or the dendritic cells can be co-incubated with the bone marrow or stem cell preparation, prior to transplantation, in order to suppress or eliminate anti-recipient donor T cells contaminating the bone marrow or stem cell preparation. The methods can be used to suppress graft versus host disease in recipients of transplanted bone marrow or stem cells, or to suppress rejection of transplanted organs or tissue.Type: GrantFiled: November 8, 2002Date of Patent: June 1, 2010Assignee: Yale UniversityInventors: Richard Leslie Edelson, Carole Berger, Michael Girardi
-
Patent number: 7727524Abstract: The present invention provides a liquid seasoning, which brings on a sufficient salty taste although it has a low sodium concentration, and which exhibits for example a pharmacological effect such as an antihypertensive effect at a high level. The present invention relates to a liquid seasoning, which contains the following components (A) to (D): (A) 3.55% or less by weight of sodium; (B) 0.5% to 4.2% by weight of potassium; (C) more than 2% by weight of an acidic amino acid and/or more than 1% by weight of a basic amino acid; and (D) 0.05% to 10% by weight of a food material having an antihypertensive effect.Type: GrantFiled: November 10, 2005Date of Patent: June 1, 2010Assignee: Kao CorporationInventors: Shigemi Tsuchiya, Youko Seo, Jun Kohori, Ryuji Ochiai, Atsushi Suzuki
-
Patent number: 7727525Abstract: The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.Type: GrantFiled: April 27, 2007Date of Patent: June 1, 2010Assignees: City of Hope, The Regents of the University of CaliforniaInventors: Anna M. Wu, Tove Olafsen, Andrew A. Raubitschek
-
Patent number: 7727526Abstract: The present invention concerns the use of a PTHrP antagonist for preparing a pharmaceutical composition for treating renal cell carcinoma (RCC) in a mammal and in particular in a human subject. Advantageously, the invention is of particular interest for inhibiting or reducing tumour growth and/or metastasis formation in kidney cancer and its metastatic developments, in particular in the lung and the liver.Type: GrantFiled: July 4, 2003Date of Patent: June 1, 2010Assignees: Universite Louis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM), Hopitaux Universitaires de StrasbourgInventors: Thierry Massfelder, Herve Lang, Eric Schordan, Jean-Jacques Helwig
-
Patent number: 7727527Abstract: The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient.Type: GrantFiled: May 9, 2002Date of Patent: June 1, 2010Assignee: Genentech, Inc.Inventor: David L. Shelton
-
Patent number: 7727528Abstract: Labeled antibodies, antibody fragments or peptides binding to soluble cytokines or cytokine receptors are used to diagnose whether a patient has cancer or an autoimmune disease. In a preferred embodiment, a radiolabelled tag that is chemically bound to a peptide, antibody, or antibody fragment specific for sTNFR-1 and/or sTNFR2 is injected into a patient with a tumor, or suspected tumor, or with any disease associated with STNF-1/STNF-2. The patient is then imaged using standard nuclear imaging equipment to detect areas or sites of concentration of the radiolabel and/or receptor/inhibitor and/or antigen. By screening for cancer by the substances it produces, using an injected antibody to that substance with a tracer attached to it, one can detect cancer at a very early stage, potentially even microscopically.Type: GrantFiled: July 20, 2005Date of Patent: June 1, 2010Assignee: Early Detection, LLCInventor: Deborah Kay Adcock
-
Patent number: 7727529Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines.Type: GrantFiled: May 28, 2008Date of Patent: June 1, 2010Assignee: General Antibodies and Biotechnologies S.R.LInventor: Roberto Burioni
-
Patent number: 7727530Abstract: The present invention relates to a pharmaceutical composition comprising of proline or proline derivatives or their salts, esters, isomers, racemates, enantiomeres or prodrugs together with an anti-cancer ligand, preferably an antibody directed to a tumour antigen. The invention is also directed to the use of proline or proline derivatives or their salts, esters, isomers or prodrugs for the manufacture of a pharmaceutical composition for treating cancer and to a method of cancer treatment by administering said composition.Type: GrantFiled: June 8, 2005Date of Patent: June 1, 2010Inventor: Zoser B. Salama
-
Patent number: 7727531Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.Type: GrantFiled: October 24, 2008Date of Patent: June 1, 2010Assignee: Valorisation-Recherche, Societe En commanditeInventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
-
Patent number: 7727532Abstract: Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.Type: GrantFiled: August 2, 2007Date of Patent: June 1, 2010Assignees: University of Massachusetts, Centers for Disease Control and PreventionInventors: William D. Thomas, Jr., Donna M. Ambrosino, Robert Mandell, Susan Sloan, Gregory J. Babcock, Charles Rupprecht
-
Patent number: 7727533Abstract: Described is a family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family is STEAP-1, which appears to be a type IIIa membrane protein. STEAP-1 is a 339 amino acid protein. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.Type: GrantFiled: May 28, 2004Date of Patent: June 1, 2010Assignee: Genentech, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Steven Chappell Mitchell
-
Patent number: 7727534Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.Type: GrantFiled: May 30, 2007Date of Patent: June 1, 2010Assignee: Oncolytics Biotech Inc.Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
-
Patent number: 7727535Abstract: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.Type: GrantFiled: June 14, 2004Date of Patent: June 1, 2010Assignee: WyethInventors: Gray Shaw, Dianne Sako, Ravindra Kumar, Jin Xu
-
Patent number: 7727536Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.Type: GrantFiled: September 29, 2006Date of Patent: June 1, 2010Assignee: Genentech, Inc.Inventors: Napoleone Ferrara, Colin Watanabe, William I. Wood
-
Patent number: 7727537Abstract: A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition preferably comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as methods of administering active agents topically or transdermally.Type: GrantFiled: October 27, 2005Date of Patent: June 1, 2010Assignee: DPM Therapeutics Corp.Inventor: Pankaj Modi
-
Patent number: 7727538Abstract: A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secretion by mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.Type: GrantFiled: September 11, 2006Date of Patent: June 1, 2010Assignee: Syntaxin Ltd.Inventors: Conrad Padraig Quinn, Keith Alan Foster, John Chaddock
-
Patent number: 7727539Abstract: A bioresorbable composite of a non-crystalline calcium phosphate ceramic synthesized within an encapsulating microspheres of bioresorbable polymeric material for use in bone repair and replacement is provided. Also provides are methods for producing these composites as well as porous, 3-dimensional scaffold produced by sintering together microspheres of this bioresorbable composite.Type: GrantFiled: March 14, 2002Date of Patent: June 1, 2010Assignee: Drexel UniversityInventors: Cato T. Laurencin, Archel M. A. Ambrosio, Janmeet S. Sahota
-
Patent number: 7727540Abstract: Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants.Type: GrantFiled: November 19, 2001Date of Patent: June 1, 2010Assignees: Universite de Geneve, Ecole Polytechnique Federale de LausanneInventors: Pierre Descouts, Björn-Owe Aronsson, Michael Grätzel, Carine Viornery, Peter Péchy
-
Patent number: 7727541Abstract: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions, which in turn contain at least one block copolymer. The block copolymer includes (a) at least one high Tg (glass transition temperature) polymer block that contains at least one high Tg vinyl ether monomer and (b) at least one low Tg polymer block that contains at least one low Tg vinyl ether monomer.Type: GrantFiled: May 18, 2006Date of Patent: June 1, 2010Assignee: Boston Scientific Scimed, Inc.Inventors: Robert E. Richard, Marlene C. Schwarz, Mark Boden
-
Patent number: 7727542Abstract: A bioactive material is made using fibroin solutions and suspensions that can be used alone or as a composite with particles such as core/shell particles. The material is designed to support the constructions, repair, regeneration or augmentation of bone and other tissues of the body. The solutions and suspensions can be loaded with core/shell-type particles comprising inorganic core materials that are coated with biodegradable polymers with an outer coating of a calcium phosphate precursor. The fibroin solutions, suspensions, and composites can be injected to fill cavities or to replace missing tissue. After injection, the materials can produce a scaffold capable of promoting tissue regeneration while degrading. The degradation of the particles, when present, can generate additional porosity within the scaffold and release other compounds in a controlled manner to enhance growth and activation of the cells necessary for tissue repair.Type: GrantFiled: October 25, 2002Date of Patent: June 1, 2010Assignee: University of ConnecticutInventors: Anthony T. DiBenedetto, Samuel Jien-shek Huang, Claudio Migliaresi, Antonella Motta
-
Patent number: 7727543Abstract: A biodegradable carrier is produced for preservation and/or controlled delivery of biologically active agents where said biodegradable carrier is a silica xerogel which is made from water and silane by using acid or base as a catalyst, and biologically active agents in said biodegradable carrier are infecting and/or transfecting viruses. Silica xerogel material can be pharmaceutically acceptable and it can be used as a medicine.Type: GrantFiled: December 23, 2008Date of Patent: June 1, 2010Assignee: DelSiTech OyInventors: Mika Koskinen, Eija Säilynoja, Manja Ahola, Harry Jalonen, Jukka Salonen, Veli-Matti Kähäri
-
Patent number: 7727544Abstract: The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment and/or prevention of myopia. An activating energy source is utilized to photopolymerize or crosslink molecules in the sclera, thereby increasing the strength of the tissue. The individual is administered a crosslinking reagent or photopolymerizable molecule that becomes associated with the membrane, which is then precisely exposed to an energy source, such as light or ultrasound.Type: GrantFiled: May 9, 2005Date of Patent: June 1, 2010Assignees: The Regents of the University of California, California Institute of TechnologyInventors: Daniel M. Schwartz, Chang Jun Yu, Robert H. Grubbs, Julia A. Kornfield, Scott E. Fraser, Matthew S. Mattson
-
Patent number: 7727545Abstract: A polymeric material having improved gas permeability comprises units of fluorinated dioxole. The polymeric material may further comprise units of a hydrophobic monomer, a hydrophilic monomer, or combinations thereof. Such a polymeric material is desirably used to produce medical devices, such as ophthalmic devices that provide increased comfort to a user.Type: GrantFiled: February 22, 2006Date of Patent: June 1, 2010Assignee: Bausch & Lomb IncorporatedInventors: Joseph C. Salamone, Derek A. Schorzman
-
Patent number: 7727546Abstract: Individualized responsive dosing dietary supplement systems, compositions, methods of dosing, and processes of producing the same, which allow a consumer to generate individualistic biological responses/effects. More specifically, a dietary supplement system for generating individualized biological conditions/responses which utilizes ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, and/or other nutrients in a bio-active delivery system which preferably avoids first pass metabolism, such that an individual may take multiple doses of the same or different dietary supplement based on varying desired biological response within each 24 hour period is also disclosed.Type: GrantFiled: July 7, 2006Date of Patent: June 1, 2010Assignee: Micro Nutrient, LLCInventors: Ricky Dean Moneymaker, Larry Scott Klesman, Jon Scott Theus
-
Patent number: 7727547Abstract: A tissue-adhesive formulation consists of a naturally occurring or synthetic polymerisable and/or cross-linkable material in particulate form, the polymerisable and/or cross-linkable material being in admixture with particulate material comprising tissue-reactive functional groups. The formulation may be used in the preparation of a tissue-adhesive sheet, by applying the formulation to at least one side of a core of a naturally occurring or synthetic polymeric material.Type: GrantFiled: April 2, 2004Date of Patent: June 1, 2010Assignee: Tissuemed LimitedInventors: David Harry Fortune, Graeme Kettlewell, David John Mandley, Ian Thompson, Diane Cook
-
Patent number: 7727548Abstract: The present invention provides a quickly disintegrating tablet which has quick disintegrability and solubility in an oral cavity, and does not have uncomfortable tastes such as bitterness, has a small variation of a tablet physical property even in storage under a humidifying condition, and has substantially no change in a medicine content in the tablet and tablet appearance and which is superior in stability; and a manufacturing method of the tablet. That is, it provides: a quickly disintegrating tablet which is prepared by blending a medicine with a saccharide and polyvinyl alcohol, which has small variations of tablet weight, tablet hardness, tablet diameter and tablet thickness, and which is superior in medicine stability in the tablet; and a manufacturing method of the tablet.Type: GrantFiled: March 1, 2001Date of Patent: June 1, 2010Assignee: Eisai R&D Management Co., Ltd.Inventors: Yutaka Morita, Masanobu Yasui, Takayuki Ohwaki, Yuki Tsushima
-
Patent number: 7727549Abstract: Otic compositions are disclosed. The compositions contain an otic drug and a carrier comprising a low molecular weight compound. The compositions do not drain out of the ear after administration.Type: GrantFiled: June 30, 2003Date of Patent: June 1, 2010Assignee: Alcon, Inc.Inventor: Bhagwati P. Kabra
-
Patent number: 7727550Abstract: The present disclosure relates to a biologically active biomatrix composition. In one embodiment, the biomatrix composition is derived from human amnions. The biomatrix is termed HuBiogel™. The composition of HuBiogel™ closely mimics naturally occurring basement membrane compositions and is capable of supporting a wide variety of cell types in vitro and in vivo. The HuBiogel™ biomatrix disclosed comprises, in one embodiment, laminin, collagen I, and collagen IV, and may further comprise any combination of the following: entactin, tenascin, fibronectin and proteoglycans. The biomatrix composition is essentially free of endogenous growth factors and proteolytic enzymes. Also described are two- and three-dimensional culture systems and physiological/pathological model systems utilizing the HuBiogel™ compositions.Type: GrantFiled: February 23, 2004Date of Patent: June 1, 2010Assignee: The UAB Research FoundationInventors: Gene P. Siegal, Raj Singh
-
Patent number: 7727551Abstract: The present invention relates to modified-release oral pharmaceutical compositions containing one or more active principles solubilized, suspended or embedded in a suitably formulated amphiphilicmatrix which, loaded in hydrophilic matrices, provides different release profiles.Type: GrantFiled: June 19, 2002Date of Patent: June 1, 2010Assignee: Farmatron Ltd.Inventor: Maria Gabriella Massironi
-
Patent number: 7727552Abstract: A composition of an oral medicine or an oral medicine which can prevent an unpleasant taste of the medicine is herein disclosed. It is granules, powders, syrups and the like which is prevented from an unpleasant taste, comprising a basic medicine having an unpleasant taste and an anionic polymer such as carrageenan.Type: GrantFiled: March 26, 1998Date of Patent: June 1, 2010Assignee: Eisai R&D Management Co., Ltd.Inventors: Koji Ukai, Tsutomu Hrada, Yasuyuki Suzuki
-
Patent number: 7727553Abstract: The present invention provides oral preparations with good disintegration containing a slightly water-soluble active ingredient, which comprise a mixture of a solid formed product (e.g. a granule) and a second disintegrant wherein said solid formed product comprises a slightly water-soluble active ingredient, a first disintegrant and a water-soluble excipient which is formed by using a water-soluble polymer binder; or comprises a solid formed product prepared from a slightly water-soluble active ingredient, a disintegrant and a sugar alcohol by using a water-soluble polymer binder. When orally administered, these oral preparations exhibit excellent dissolution characteristics of the active ingredient in the digestive tract, and further, these preparations can show equivalent dissolution profile even at different amounts of the active ingredient, and thus enable the selection of the most suitable medicament for each patient, which makes these preparations highly useful in the clinical field.Type: GrantFiled: September 14, 2001Date of Patent: June 1, 2010Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventor: Kazuyuki Fujihara
-
Patent number: 7727554Abstract: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.Type: GrantFiled: December 21, 2004Date of Patent: June 1, 2010Assignee: Board of Regents of the University of Nebraska by and Behalf of the University of Nebraska Medical CenterInventors: Vinod D. Labhasetwar, Sanjeeb K. Sahoo, Maram K. Reddy
-
Patent number: 7727555Abstract: Particles and related methods are disclosed. In some embodiments, a method of making particles can include forming a stream of a mixture including first and second materials, exposing the stream to a vibration, and treating the stream to form particles. The vibration can have, for example, a sinusoidal, triangular, and/or sawtooth waveform.Type: GrantFiled: April 21, 2005Date of Patent: June 1, 2010Assignee: Boston Scientific SciMed, Inc.Inventors: Paul DiCarlo, Janel Lanphere, Thomas V. Casey, II, Marcia Buiser, Erin McKenna
-
Patent number: 7727556Abstract: A pharmaceutical composition having improved solubility comprising a hydrophobic drug or pharmaceutically acceptable salt thereof and a compound having at least one carboxylic acid moiety, wherein the molar ratio of the compound having at least one carboxylic acid moiety to the hydrophobic drug or pharmaceutically acceptable salt thereof is from about 0.1:1 to about 25:1. The pharmaceutical composition exhibits rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.Type: GrantFiled: May 6, 2005Date of Patent: June 1, 2010Assignee: Sandoz AGInventors: Gary Barbera, Chetan Chhabildas Doshi, Mahendra R Patel, Pablo Davila, Satishkumar Ambalal Patel
-
Patent number: 7727557Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.Type: GrantFiled: September 22, 2006Date of Patent: June 1, 2010Assignee: Purdue Pharma LPInventor: Richard Sackler
-
Patent number: 7727558Abstract: Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: January 31, 2007Date of Patent: June 1, 2010Assignees: Emisphere Technologies, Inc., Virginia Commonwealth UniversityInventors: Sam J. Milstein, Eugene N. Barantsevitch, Nai Fang Wang, Jun Liao, John Smart, Richard Conticello, Raphael Ottenbrite
-
Patent number: 7727559Abstract: Methods and compositions useful for neuronal protection in retinal cells in vitro and the protection of mammalian cells from reactive oxygen species in vivo are provided. Ultrafine nano-size cerium oxide particles, less than 10 nanometers in diameter, have been provided to decrease reactive oxygen species (ROS) in retina tissue that generates large amounts of ROS. These reactive oxygen species (ROS) are involved in light-induced retina degeneration and age-related macular degeneration (AMD). Cerium oxide nanoparticles have been used to promote the lifespan of retinal neurons and protect the neurons from apoptosis induced by hydrogen peroxide in vitro and in vivo. The neuronal protection in retinal cells is achieved by decreasing generation of intracellular reactive oxygen species (ROS). Thus, cerium oxide particles are used to promote the longevity of retinal neurons in vitro and mammalian cells in vivo.Type: GrantFiled: April 27, 2006Date of Patent: June 1, 2010Assignee: University of Central Florida Research Foundation, Inc.Inventors: James F. McGinnis, Junping Chen, Lily Wong, Steve Sezate, Sudipta Seal, Swanand Patil
-
Patent number: 7727560Abstract: The present invention relates to a method of suppressing malignant conditions, including cancer with complications such like hepatitis and platelet disorder in bleeding, by administering a composition of an extract of Canavalia ensiformis. Also, the invention is nontoxic to the individual and for improving functions of kidney as well as of liver, especially when involved in cancer.Type: GrantFiled: May 18, 2004Date of Patent: June 1, 2010Inventor: Sou Yi Lu
-
Patent number: 7727561Abstract: This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder.Type: GrantFiled: April 27, 2005Date of Patent: June 1, 2010Assignee: Pacific Arrow LimitedInventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
-
Patent number: 7727562Abstract: Liquid medicaments incorporate about 1.0-3.0% active benzoyl peroxide (BP) by weight in substantially fully solubilized form, while being substantially free of acetone and other harsh, dermatologically undesirable solvents. The novel compositions are produced by (a) creating an emulsion or slurry of BP in an emollient, topically acceptable ester, and (b) dissolving the emulsion or slurry in absolute alcohol. The medicaments may be used in the treatment of BP-responsive skin conditions in mammals, e.g., acne vulgaris or rosacea. The novel medicaments may be dispensed directly to the affected skin area through the use of an applicator device comprising a fluid reservoir associated with a foam applicator tip, or via a spray dispenser, atomizer or pump spray.Type: GrantFiled: June 21, 2007Date of Patent: June 1, 2010Inventor: Steven T. Blackman
-
Patent number: 7727563Abstract: One or more embodiments of the invention are directed to methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans. The methods comprise the step of administering to the patients a composition comprising a therapeutically effective amount of an extract from pomegranate.Type: GrantFiled: July 27, 2006Date of Patent: June 1, 2010Assignee: Pom Wonderful, LLCInventor: Michael Aviram
-
Patent number: 7727564Abstract: The present invention relates to stable, palatable, freeze-dried, fruit-based dietary supplements. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit and Jucara fruit.Type: GrantFiled: October 28, 2008Date of Patent: June 1, 2010Assignee: K2A LLCInventors: Kenneth A. Murdock, Alexander G. Schauss
-
Patent number: 7727565Abstract: Some embodiments provide a chewing or bubble gum composition which includes a liquid fill composition and a gum region which includes a gum base surrounding the liquid fill which may include a modified release component, wherein the gum region includes a polyol composition including at least one polyol and having a water solubility of less than 72% by weight at 25° C. The composition may also include a coating region which surrounds the gum region.Type: GrantFiled: April 21, 2006Date of Patent: June 1, 2010Assignee: Cadbury Adams USA LLCInventors: Bharat Jani, Kishor Kabse
-
Patent number: 7727566Abstract: The present invention is directed to an energy bar having a mean hedonic score for consumer acceptability of at least about 5.2. Preferably, the energy bar is either a grain based energy bar or a chewy energy bar.Type: GrantFiled: July 8, 2003Date of Patent: June 1, 2010Assignee: Mars, IncorporatedInventors: Edward L. Rapp, Jamie Troy, Jeannette Dido, Douglas Mann, Thomas Collins, Kevin Rabinovitch, Ralph Lee, Neil Willcocks, Robert Boushell, Ralph Jerome, Tiago O. Rodrigues, John M. Kaiser, Ivonne E. Nill
-
Patent number: 7727567Abstract: To establish the integrity of a product located in a container a given feature of the product in the container is determined by means of a first measurement method in which a first physical property of the product is ascertained, the given feature is additionally ascertained at least directly or by means of a second measurement method which is based on a second physical property which is different from the first physical property, and the values obtained by means of the two measurement methods of the given feature are compared. If the product is a drink in a bottle and if the given feature is the fill level, the first measurement method can consist of the fill level being measured by means of absorption of an X-ray beam, and the second measurement method can consist of the change effected by the bottle in the resonant frequency of a high-frequency oscillating circuit being measured.Type: GrantFiled: November 7, 2005Date of Patent: June 1, 2010Assignee: Heuft Systemtechnik GmbHInventor: Bernhard Heuft
-
Patent number: 7727568Abstract: The invention relates to an antimicrobial composition comprising a mixture of at least 20 wt. % lactic acid or a derivative thereof and an inorganic acid selected from a nitrogen, sulfur, and phosphorous acid, and mixtures thereof for use in animal nutrition. In one of the embodiments the composition further comprises at least one other acid selected from acetic acid, fumaric acid, gluconic acid, (iso)butyric acid, sorbic acid, (iso)valeric acid, maleic acid, malic acid, capronic acid, benzoic acid, and citric acid. In a special embodiment the composition comprises lactic acid or polylactide, which is attached to a support.Type: GrantFiled: June 4, 2004Date of Patent: June 1, 2010Assignee: Purac Biochem B.V.Inventor: Anne Cazemier
-
Patent number: 7727569Abstract: It is intended to provide a procedure for, in the fractionation of vegetable butter, transesterified fat or oil, isomerized hydrogenated fat or oil, etc. without the use of solvents, obtaining high-concentration component G2U (defined below) by concentrating operation through reduction of the amount of liquid component residue in crystal portion. There is provided a method of dry fractionation of fat or oil characterized in that fat or oil (A) containing components G2U and GU2 is fractionated through crystallization/solid-liquid separation into crystal fraction of concentrated G2U (AF) and liquid fraction of concentrated GU2 (AL), subsequently this crystal fraction (AF) is mixed with liquid G2U-containing fat or oil (B) whose GU2 concentration is lower than that of the liquid fraction (AL) and thereafter the mixture is separated into crystal fraction (BF) and liquid fraction (BL).Type: GrantFiled: December 15, 2004Date of Patent: June 1, 2010Assignee: Fuji Oil Company, LimitedInventors: Yuji Kuwabara, Nobuaki Kanai, Toshiaki Takahashi, Yoshihiro Yamanaka
-
Patent number: 7727570Abstract: A process for the preparation of a bake stable nut butter emulsion which comprises the following steps (a) selecting a sugar syrup solution and diluting it with water until it contains an amount of sugar solids which is in the range 55-80 wt. %, (b) heating the solution to a temperature in the range 40-100° C., (c) dispersing a starch into the heated solution until it contains 1-5 wt. % of dissolved starch, (d) dispersing an emulsifier into the heated solution until it contains 0.5-3 wt. % of dissolved emulsifier, (e) dispersing a gelling agent into the heated solution until it contains 0.2-1 wt. % of dissolved gelling agent, (f) cooling the heated solution into which the starch, emulsifier and gelling agent have been dispersed to a temperature which is in the range of 20-50° C.Type: GrantFiled: December 7, 2006Date of Patent: June 1, 2010Assignee: Unilever Bestfoods, North America, division of Conopco, Inc.Inventor: Arjan Johannes Louter
-
Patent number: 7727571Abstract: Antioxidant polymers of the present invention comprise repeat units that include one or both of Structural Formulas (I) and (II): wherein: R is —H or a substituted or unsubstituted alkyl, acyl or aryl group; Ring A is substituted with at least one tert-butyl group or substituted or unsubstituted n-alkoxycarbonyl group; Ring B is substituted with at least one —H and at least one tert-butyl group or substituted or unsubstituted n-alkoxycarbonyl group; Rings A and B are each optionally substituted with one or more groups selected from the group consisting of —OH, —NH, —SH, a substituted or unsubstituted alkyl or aryl group, and a substituted or unsubstituted alkoxycarbonyl group; n is an integer equal to or greater than 2; and p is an integer equal to or greater than 0. The invention also includes methods of using and preparing these polymers.Type: GrantFiled: February 27, 2007Date of Patent: June 1, 2010Assignees: University of Massachusetts Lowell, The United States of America as represented by the Secretary of the ArmyInventors: Ashok L. Cholli, Vijayendra Kumar, Javant Kumar, Virinder Singh Parmar, Lynne Ann Samuelson, Ferdinando F. Bruno